LGALS3BP, lectin galactoside-binding soluble 3 binding protein, promotes oncogenic cellular events impeded by antibody intervention

[1]  N. Awasthi,et al.  Enhancing sorafenib-mediated sensitization to gemcitabine in experimental pancreatic cancer through EMAP II , 2013, Journal of experimental & clinical cancer research : CR.

[2]  S. Goodman,et al.  Integrins as therapeutic targets. , 2012, Trends in pharmacological sciences.

[3]  Z. Werb,et al.  The extracellular matrix: A dynamic niche in cancer progression , 2012, The Journal of cell biology.

[4]  S. Moestrup,et al.  The Conserved Scavenger Receptor Cysteine-Rich Superfamily in Therapy and Diagnosis , 2011, Pharmacological Reviews.

[5]  S. Niland,et al.  Integrin-Mediated Cell-Matrix Interaction in Physiological and Pathological Blood Vessel Formation , 2011, Journal of oncology.

[6]  Benjamin Geiger,et al.  Molecular architecture and function of matrix adhesions. , 2011, Cold Spring Harbor perspectives in biology.

[7]  W. English,et al.  MT1-MMP regulates VEGF-A expression through a complex with VEGFR-2 and Src , 2010, Journal of Cell Science.

[8]  Kumaran Kandasamy,et al.  SILAC-based quantitative proteomic approach to identify potential biomarkers from the esophageal squamous cell carcinoma secretome , 2010, Cancer biology & therapy.

[9]  T. Meyer,et al.  Identification of Mac-2-binding Protein as a Putative Marker of Neuroendocrine Tumors from the Analysis of Cell Line Secretomes* , 2009, Molecular & Cellular Proteomics.

[10]  Richard O. Hynes,et al.  The Extracellular Matrix: Not Just Pretty Fibrils , 2009, Science.

[11]  S. Van slambrouck,et al.  Reorganization of the integrin alpha2 subunit controls cell adhesion and cancer cell invasion in prostate cancer. , 2009, International journal of oncology.

[12]  Risto Penttinen,et al.  Extracellular Matrix Molecules: Potential Targets in Pharmacotherapy , 2009, Pharmacological Reviews.

[13]  Donald J. Johann,et al.  Cancer and the tumor microenvironment: a review of an essential relationship , 2009, Cancer Chemotherapy and Pharmacology.

[14]  M. Lai,et al.  The cancer secretome: a reservoir of biomarkers , 2008, Journal of Translational Medicine.

[15]  Michael R Barnes,et al.  Drug discovery in the extracellular matrix. , 2008, Drug discovery today.

[16]  J. Cardelli,et al.  The β1 Integrin Activates JNK Independent of CagA, and JNK Activation Is Required for Helicobacter pylori CagA+-induced Motility of Gastric Cancer Cells* , 2008, Journal of Biological Chemistry.

[17]  M. Scully,et al.  The Role of Integrins in Cancer and the Development of Anti-Integrin Therapeutic Agents for Cancer Therapy , 2008, Perspectives in medicinal chemistry.

[18]  Zigang Dong,et al.  The functional contrariety of JNK , 2007, Molecular carcinogenesis.

[19]  E. Lee,et al.  Serum galectin-3 and galectin-3 binding protein levels in Behçet's disease and their association with disease activity. , 2007, Clinical and experimental rheumatology.

[20]  E. Diamandis,et al.  Discovery of candidate tumor markers for prostate cancer via proteomic analysis of cell culture-conditioned medium. , 2007, Clinical chemistry.

[21]  S. Paik,et al.  Up‐regulation of Mac‐2 binding protein by hTERT in gastric cancer , 2007, International journal of cancer.

[22]  R. Chibbar,et al.  Tumor‐associated antigen 90K/Mac‐2‐binding protein: Possible role in colon cancer , 2006, Journal of cellular biochemistry.

[23]  Y. Eguchi,et al.  Transforming growth factor‐β1‐induced apoptosis is blocked by β1‐integrin‐mediated mitogen‐activated protein kinase activation in human hepatoma cells , 2004, Cancer science.

[24]  Troels Z. Kristiansen,et al.  Mac‐2‐binding protein is a diagnostic marker for biliary tract carcinoma , 2004, Cancer.

[25]  R. Gay,et al.  Galectin 3 and its binding protein in rheumatoid arthritis. , 2003, Arthritis and rheumatism.

[26]  Fenghua Wang,et al.  [Predictive significance of serum 90K/Mac-2BP on chemotherapy response in non-Hodgkin's lymphoma]. , 2003, Ai zheng = Aizheng = Chinese journal of cancer.

[27]  C. Rüegg,et al.  Vascular integrins: pleiotropic adhesion and signaling molecules in vascular homeostasis and angiogenesis , 2003, Cellular and Molecular Life Sciences CMLS.

[28]  J. Hanaoka,et al.  Expression and immunogenicity of a tumor‐associated antigen, 90K/Mac‐2 binding protein, in lung carcinoma , 2002, Cancer.

[29]  A. Mould.  Analyzing Integrin‐Dependent Adhesion , 2002, Current protocols in cell biology.

[30]  G. Giannelli,et al.  Localization and possible role of two different alpha v beta 3 integrin conformations in resting and resorbing osteoclasts. , 2002, Journal of cell science.

[31]  N. Tinari,et al.  Expression of the 90K tumor-associated protein in benign and malignant melanocytic lesions. , 2002, The Journal of investigative dermatology.

[32]  A. Marchetti,et al.  Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage I non-small cell lung cancer patients. , 2002, Cancer research.

[33]  David A. Cheresh,et al.  Role of integrins in cell invasion and migration , 2002, Nature Reviews Cancer.

[34]  S. Dreskin,et al.  Isoforms of Jun Kinase Are Differentially Expressed and Activated in Human Monocyte/Macrophage (THP-1) Cells1 , 2001, The Journal of Immunology.

[35]  M. Correale,et al.  Serum 90K/MAC-2BP Glycoprotein in Patients with Liver Cirrhosis and Hepatocellular Carcinoma: a Comparison with α-Fetoprotein , 2001, Clinical chemistry and laboratory medicine.

[36]  N. Tinari,et al.  Adhesion to 90K (Mac-2 BP) as a mechanism for lymphoma drug resistance in vivo. , 2000, Blood.

[37]  R. Birge,et al.  Integrin-mediated Activation of Focal Adhesion Kinase Is Required for Signaling to Jun NH2-terminal Kinase and Progression through the G1 Phase of the Cell Cycle , 1999, The Journal of cell biology.

[38]  S. Iacobelli,et al.  Elevated Levels of Circulating Immunostimulatory 90K in Henoch–Schoenlein Purpura , 1999, Journal of Clinical Immunology.

[39]  R. Timpl,et al.  Mac‐2 binding protein is a cell‐adhesive protein of the extracellular matrix which self‐assembles into ring‐like structures and binds β1 integrins, collagens and fibronectin , 1998, The EMBO journal.

[40]  A. Ullrich,et al.  The secreted tumor-associated antigen 90K is a potent immune stimulator. , 1994, The Journal of biological chemistry.

[41]  P. Sismondi,et al.  Prognostic value of a novel circulating serum 90K antigen in breast cancer. , 1994, British Journal of Cancer.

[42]  S. Iacobelli,et al.  90K protein: a new predictor marker of disease progression in human immunodeficiency virus infection. , 1993, Journal of acquired immune deficiency syndromes.

[43]  S. Iacobelli,et al.  Measurement of a monoclonal-antibody-defined antigen (90K) in the sera of patients with ovarian cancer. , 1988, Anticancer research.

[44]  C. Carlin,et al.  Identification of a 90 000-Dalton cell surface glycoprotein with elevated expression in human hepatoma cells. , 1983, Experimental cell research.

[45]  N. Tinari,et al.  LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis , 2012, Journal of Molecular Medicine.

[46]  Cheryl F. Lichti,et al.  The Prostate 71 : 711 ^ 721 ( 2011 ) Co-PurificationofMac-2 Binding Protein WithGalectin-3 andAssociationWith Prostasomes inHumanSemen , 2011 .

[47]  Fadlo R Khuri,et al.  Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. , 2006, Cancer research.

[48]  Stefano Iacobelli,et al.  90K (Mac-2 BP) and galectins in tumor progression and metastasis , 2004, Glycoconjugate Journal.

[49]  Jiahuai Han,et al.  The p38 signal transduction pathway: activation and function. , 2000, Cellular signalling.

[50]  A. Mould,et al.  Solid phase assays for studying ECM protein-protein interactions. , 2009, Methods in molecular biology.